24 results about "PDE1" patented technology

The disclosure relates to the use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of cancers and tumors, including for inhibiting tumor recruitment of macrophages and other cells to the tumor or cancer, for complementing and enhancing checkpoint inhibitor therapies, and for mitigating the side effects (i.e., inflammatory-related adverse events) associated with checkpoint inhibitor therapies.

The disclosure provides the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment and prophylaxis of diseases or disorders characterized by inflammation, including methods of treatment and pharmaceutical compositions for use therein.

The disclosure relates to the combination of inhibitors of phosphodiesterase 1 (PDE1) useful for the treatment of certain cancers or tumors, such as colon cancer. In another embodiment, the disclosure relates to the use of inhibitors of PDE1 and an optional antitumor agent for the treatment of certain cancers or tumors.

The disclosure relates to the use of phosphodiesterase 1 (PDE1) inhibitors for preventing or treating chemobrain, e.g., inhibiting or mitigating one or more symptoms of chemobrain, e.g., feeling of mental fogginess, deficit in attention, disorganized behavior or thinking, confusion, impaired concentration, difficulty finding the right word, difficulty learning new skills, difficulty multitasking, memory impairment (e.g., short-term memory problems, long-term memory problems, impaired verbal memory, impaired visual memory), and / or fatigue.

The disclosure provides the administration of inhibitors of phosphodiesterase 1 (PDE1) for the treatment and prophylaxis of diseases or disorders characterized by inflammation, including methods of treatment and pharmaceutical compositions for use therein.

The disclosure relates to the combination of phosphodiesterase 1 (PDE1) inhibitors, which is useful for treating certain cancers or tumors, such as colon cancer. In another form, the disclosure relates to the use of PDE1 inhibitors and an optional antitumor agent for treating certain cancers or tumors.

Substituted furopyrimidine chemical entities of general formula (I): wherein R a has any of the values described herein, and compositions comprising such chemical entities; methods for preparing them; and their use in various methods, including metabolic and reaction kinetics studies; detection and imaging techniques; radiotherapy; modulating and treating disorders mediated by PDE1 activity or dopaminergic signaling; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent loss of function; treating stroke, including cognitive and motor function deficits during stroke rehabilitation; promoting neuroprotection and neurorestoration; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including cardiovascular disorders, renal disorders, hematological disorders, gastrointestinal disorders, liver disorders, cancer, fertility disorders, and metabolic disorders.

Please add the following heading and paragraph on a separate sheet, after the claims: The disclosure relates to the use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of cancers and tumors, including for inhibiting tumor recruitment of macrophages and other cells to the tumor or cancer, for complementing and enhancing checkpoint inhibitor therapies, and for mitigating the side effects (i.e., inflammatory-related adverse events) associated with checkpoint inhibitor therapies.

The disclosure provides methods, treatments and materials for enhancing the effect of an adenosine A2 receptor agonist in the treatment, mitigation or prophylaxis of a disease or condition characterized by inotropic and / or lusitropic dysfunction, and / or enhancing adenosine A2 receptor function in the treatment, mitigation or prophylaxis of a disease or condition characterized by impaired adenosine A2 receptor function, comprising administration of an effective amount of a PDE1 inhibitor to a patient in need thereof, for example a patient suffering from heart failure.

The disclosure relates to the use of phosphodiesterase 1 (PDE1) inhibitors in combination with a Compound of Formula VIII or a Compound of Formula IX, as described herein, or in combination with an antiemetic agent, such as an antipsychotic agent, e.g., olanzapine, for preventing or treating nausea and / or vomiting, e.g., CINV (chemotherapy-induced nausea and vomiting). In some embodiments, the Compound of Formula VIII or the Compound of Formula IX is used as mono-therapy (i.e., without a PDE1 inhibitor).

Please add the following heading and paragraph on a separate sheet, after the claims: The disclosure relates to the use of phosphodiesterase 1 (PDE1) inhibitors alone or in combination with immune checkpoint inhibitor therapies for the treatment of breast cancer, including for promoting antitumor immunity and mitigating the side effects (i.e., inflammatory-related adverse events) associated with checkpoint inhibitor therapies.

To provide a method for preventing and / or treating a condition, disease, or disorder associated with the dopamine D1 receptor intracellular pathway, for example, a condition, disease, or disorder characterized by a deficit in attention, cognition, memory, and / or inhibitory processing.SOLUTION: A method comprising administering to a subject in need of prevention and / or treatment a pharmaceutically effective amount of a phosphodiesterase 1 (PDE1) inhibitor (for example, a compound represented by formula V).SELECTED DRAWING: None

Substituted furanopyrimidine chemical entities of Formula (I):wherein Ra has any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by PDE1 activity or dopaminergic signaling; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including cardiovascular, renal, hematological, gastroenterological, liver, cancer, fertility, and metabolic disorders.

The present application belongs to the technical field of biological medicine, and particularly relates to a pyridodihydrofuranone derivative, a preparation method and application thereof. The derivative shows good inhibitory effect on phosphodiesterase type 1 (PDE1), and can be applied as a phosphodiesterase type 1 inhibitor. According to the research on phosphodiesterase type 1 related diseases in the prior art, the pyridodihydrofuranone derivative can be further applied in the treatment of pulmonary arterial hypertension, idiopathic pulmonary fibrosis, liver fibrosis, vascular dementia, intestinal inflammation and other diseases related to phosphodiesterase type 1, more optional drugs are provided, and the pyridodihydrofuranone derivative has important medicinal value and clinical application prospect. Moreover, the pyridodihydrofuranone derivative has novel structure, the preparation method is simple, and is very suitable for large-scale industrial production and application.

The disclosure relates to the use of phosphodiesterase 1 (PDE1) inhibitors for treatment or prophylaxis for a metabolic disorder (e.g., obesity, fatty liver disease, type 2 diabetes, pre-diabetic conditions, and conditions associated with fat-induced inflammation), reducing high blood glucose levels (e.g. as reflected in high fasting glucose or Hb-A1C levels), and / or promoting or maintaining body weight loss or suppressing body weight gain.

The disclosure relates to the combination of inhibitors of phosphodiesterase 1 (PDE1) useful for the treatment of certain cancers or tumors, such as gliomas. In another embodiment, the disclosure relates to the combination of inhibitors of PDE1 and an antitumor agent for the treatment of certain cancers or tumors, such as gliomas.